Shree Ganesh Remedies Ltd

Shree Ganesh Rem, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting recent financial and technical developments. The stock’s assessment has shifted following a series of quarterly results and market performance indicators that have drawn attention to its current standing within the sector.

Shree Ganesh Remedies touched a fresh 52-week low of Rs.442.1 today, marking a significant decline in its stock price amid a sustained downward trend over recent sessions. The pharmaceutical company’s shares have been under pressure, reflecting a series of financial results and market dynamics that have influenced its valuation.

Shree Ganesh Remedies has hit a new 52-week low, reflecting a significant downturn in its stock performance amid broader market trends. The company has seen a notable decline in profitability, with profits before and after tax decreasing substantially. Despite these challenges, it maintains a low debt to EBITDA ratio.

Shree Ganesh Remedies has reached a new 52-week low, reflecting a challenging year with a significant decline in stock price. The company has reported negative results for the last three quarters, and its low Debt to EBITDA ratio indicates strong debt servicing ability, despite caution from institutional investors.

Shree Ganesh Remedies has reached a new 52-week low, reflecting a challenging year with a significant decline in stock price. The company has reported negative results for the last three quarters, and its stock continues to underperform in the market, indicating ongoing difficulties in regaining investor confidence.

Shree Ganesh Remedies has hit a new 52-week low, reflecting a challenging year with a significant decline in stock price. The company has underperformed its sector and reported negative results for three consecutive quarters, raising concerns about its financial health and investor confidence.

Shree Ganesh Remedies has hit a new 52-week low, reflecting a challenging year with a significant stock price decline. The company has underperformed its sector and reported negative financial results for three consecutive quarters, raising concerns among investors despite a low debt-to-equity ratio.

Shree Ganesh Remedies Limited, a Gujarat-based pharmaceutical intermediates manufacturer with a market capitalisation of ₹618.00 crores, reported deeply concerning results for Q2 FY2026, with consolidated net profit plummeting 47.65% quarter-on-quarter to ₹3.45 crores from ₹6.59 crores in Q1 FY2026. The year-on-year comparison proved equally dismal, with profits declining 25.81% from ₹4.65 crores in Q2 FY2025. The stock has responded brutally to deteriorating fundamentals, collapsing 38.64% over the past year and trading at ₹489.10 as of November 7, 2025—a staggering 48.52% below its 52-week high of ₹950.00.

Shree Ganesh Remedies has reached a new 52-week low, reflecting a significant decline in its stock performance. Over the past year, the company has experienced a notable drop, with key financial metrics indicating challenges, including decreased profit and net sales. The stock is trading below multiple moving averages, raising concerns among investors.

Shree Ganesh Remedies has hit a new 52-week low, reflecting a significant decline in its stock performance. The company has underperformed its sector and reported a substantial drop in both profit and net sales over the past six months, indicating ongoing financial challenges.

Shree Ganesh Remedies has reached a new 52-week low, reflecting a significant downturn in its stock performance. The company has underperformed its sector and reported a notable decline in profitability and net sales over the past six months, while maintaining a low debt-to-equity ratio.

Shree Ganesh Remedies has hit a new 52-week low, reflecting a significant downturn in its stock performance. The company has underperformed its sector and experienced a notable decline over the past year, alongside a decrease in net sales and profit after tax. Its valuation remains high compared to peers.